Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $45.00 at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by HC Wainwright from $41.00 to $45.00 in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also commented on SNDX. Barclays raised their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an overweight rating in a research note on Thursday. Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a buy rating in a research note on Wednesday, June 26th. Citigroup cut their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a buy rating on the stock in a research note on Thursday, May 9th. Scotiabank lowered Syndax Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, June 14th. Finally, JPMorgan Chase & Co. cut their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an overweight rating on the stock in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $35.33.

Syndax Pharmaceuticals Stock Down 0.2 %

SNDX stock opened at $19.93 on Thursday. The business’s fifty day simple moving average is $21.22 and its two-hundred day simple moving average is $21.69. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.34. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -6.19 and a beta of 0.94.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. During the same quarter last year, the firm posted ($0.64) EPS. The firm’s revenue for the quarter was up 3499999990.0% on a year-over-year basis. Research analysts expect that Syndax Pharmaceuticals will post -3.64 EPS for the current year.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan purchased 1,250 shares of the stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $20.03 per share, with a total value of $25,037.50. Following the completion of the acquisition, the chief financial officer now owns 52,623 shares in the company, valued at $1,054,038.69. The acquisition was disclosed in a filing with the SEC, which is available at this link. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System lifted its holdings in shares of Syndax Pharmaceuticals by 5.3% during the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock worth $357,000 after purchasing an additional 835 shares during the period. Sei Investments Co. lifted its holdings in shares of Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after purchasing an additional 991 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Syndax Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock worth $1,822,000 after purchasing an additional 1,150 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Syndax Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock worth $305,000 after purchasing an additional 1,162 shares during the period. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals during the second quarter worth about $27,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).